Market closedNon-fractional
TransMedics Group/TMDX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About TransMedics Group
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Ticker
TMDX
Sector
Healthcare
Trading on
NASDAQ
Industry
Health Care Equipment and Supplies
Headquarters
Andover, United States
Employees
584
Website
www.transmedics.com
TMDX Metrics
BasicAdvanced
$4.8B
Market cap
-
P/E ratio
-$0.32
EPS
1.87
Beta
-
Dividend rate
Price and volume
Market cap
$4.8B
Beta
1.87
Financial strength
Current ratio
9.723
Quick ratio
8.605
Long term debt to equity
322.402
Total debt to equity
323.71
Interest coverage (TTM)
1.13%
Management effectiveness
Return on assets (TTM)
1.85%
Return on equity (TTM)
-5.79%
Valuation
Price to revenue (TTM)
16.05
Price to book
30.02
Price to tangible book (TTM)
32.97
Price to free cash flow (TTM)
-20.71
Growth
Revenue change (TTM)
149.23%
Earnings per share change (TTM)
-65.82%
3-year revenue growth (CAGR)
127.67%
3-year earnings per share growth (CAGR)
-33.21%
What the Analysts think about TMDX
Analyst Ratings
Majority rating from 8 analysts.
TMDX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$97M
19.36%
Net income
$12M
202.50%
Profit margin
12.50%
153.55%
TMDX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.03
-$0.78
$0.12
$0.35
-
Expected
-$0.13
-$0.16
-$0.06
-$0.04
$0.20
Surprise
-76.92%
382.47%
-293.55%
-975.00%
-
TMDX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for TransMedics Group stock?
TransMedics Group (TMDX) has a market cap of $4.8B as of July 27, 2024.
What is the P/E ratio for TransMedics Group stock?
The price to earnings (P/E) ratio for TransMedics Group (TMDX) stock is 0 as of July 27, 2024.
Does TransMedics Group stock pay dividends?
No, TransMedics Group (TMDX) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next TransMedics Group dividend payment date?
TransMedics Group (TMDX) stock does not pay dividends to its shareholders.
What is the beta indicator for TransMedics Group?
TransMedics Group (TMDX) has a beta rating of 1.87. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell TransMedics Group stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.